Literature DB >> 22901190

Expression of matrix metalloproteinase-2, but not caspase-3, facilitates distinction between benign and malignant thyroid follicular neoplasms.

Sanaz Sanii1, Hiva Saffar, Hedieh M Tabriz, Mostafa Qorbani, Vahid Haghpanah, Seyed M Tavangar.   

Abstract

PURPOSE: Definite diagnosis of follicular thyroid carcinoma (FTC) is based on the presence of capsular or vascular invasion. To date, no reliable and practical method has been introduced to discriminate this malignant neoplasm from follicular thyroid adenoma (FTA) in fine needle aspiration biopsy material. Matrix metalloproteinase-2 (MMP-2), by degrading extracellular matrix, and caspase-3, by induction of apoptosis, have been shown to play important roles in carcinogenesis and aggressive behavior in many tumor types. The aim of this study was to examine expression of MMP-2 and caspase-3 in thyroid follicular neoplasms and to determine their usefulness for differential diagnosis.
METHOD: Sixty FTAs and 41 FTCs were analysed immunohistochemically for MMP-2 and caspase-3. RESULT: MMP-2 was positive in 4 FTCs (9.8%), but in none of FTAs, with statistical significance (p=0.025). Caspase-3 was positive in 30 (50%) of FTAs and in 27 (65.9%) of FTCs.
CONCLUSION: Our results show MMP-2 expression only in FTCs and suggest that this protein may be a useful marker to confirm diagnosis of FTC versus FTA with 100% specificity and 100% predictive value of a positive test. We failed to show any differential diagnostic value for caspase-3 in thyroid follicular neoplasms.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22901190     DOI: 10.7314/apjcp.2012.13.5.2175

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  10 in total

1.  Meta-analysis of promoter methylation in eight tumor-suppressor genes and its association with the risk of thyroid cancer.

Authors:  Fatemeh Khatami; Bagher Larijani; Ramin Heshmat; Abbasali Keshtkar; Mahsa Mohammadamoli; Ladan Teimoori-Toolabi; Shirzad Nasiri; Seyed Mohammad Tavangar
Journal:  PLoS One       Date:  2017-09-19       Impact factor: 3.240

2.  Genetic and Epigenetic of Medullary Thyroid Cancer

Authors:  Fatemeh Khatami; Seyed Mohammad Tavangar
Journal:  Iran Biomed J       Date:  2017-11-11

3.  Circulating Tumor BRAF Mutation and Personalized Thyroidzzm321990Cancer Treatment

Authors:  Fatemeh Khatami; Bagher Larijani; Seyed Mohammad Tavangar
Journal:  Asian Pac J Cancer Prev       Date:  2017-02-01

Review 4.  Oncometabolites as biomarkers in thyroid cancer: a systematic review.

Authors:  Fatemeh Khatami; Moloud Payab; Masoumeh Sarvari; Kambiz Gilany; Bagher Larijani; Babak Arjmand; Seyed Mohammad Tavangar
Journal:  Cancer Manag Res       Date:  2019-02-25       Impact factor: 3.989

Review 5.  Personalized treatment options for thyroid cancer: current perspectives.

Authors:  Fatemeh Khatami; Bagher Larijani; Shekoufeh Nikfar; Mandana Hasanzad; Kiarad Fendereski; Seyed Mohammad Tavangar
Journal:  Pharmgenomics Pers Med       Date:  2019-09-13

Review 6.  A Review of Driver Genetic Alterations in Thyroid Cancers.

Authors:  Fatemeh Khatami; Seyed Mohammad Tavangar
Journal:  Iran J Pathol       Date:  2018-07-17

7.  Promoter Methylation of Four Tumor Suppressor Genes in Human Papillary Thyroid Carcinoma.

Authors:  Fatemeh Khatami; Bagher Larijani; Ramin Heshmat; Shirzad Nasiri; Hiva Saffar; Gita Shafiee; Azam Mossafa; Seyed Mohammad Tavangar
Journal:  Iran J Pathol       Date:  2019-09-22

8.  Follicular Thyroid Carcinoma Metastatic to the Kidney: Report of a Case with Cytohistologic Correlation.

Authors:  Vikas Nath; Mithra Baliga; Jack Lewin; Frederico Souza; Israh Akhtar
Journal:  Case Rep Pathol       Date:  2015-10-13

Review 9.  Liquid Biopsy in Thyroid Cancer: New Insight.

Authors:  Fatemeh Khatami; Seyed Mohammad Tavangar
Journal:  Int J Hematol Oncol Stem Cell Res       Date:  2018-07-01

Review 10.  Liquid Biopsy as a Minimally Invasive Source of Thyroid Cancer Genetic and Epigenetic Alterations.

Authors:  Fatemeh Khatami; Bagher Larijani; Shirzad Nasiri; Seyed Mohammad Tavangar
Journal:  Int J Mol Cell Med       Date:  2019-05-29
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.